Why Is SOPHiA GENETICS (SOPH) Stock Up +3.84% Today?
Key Takeaways
- SOPH shares climbed 3.84%, closing at $8.65, up $0.32 from the prior session's close of $8.33.
- The stock extended its post-earnings rally, hitting a fresh 52-week intraday high of $8.68.
- Momentum continues to build on strong Q2 results, raised full-year guidance, and a new AstraZeneca companion-diagnostics partnership.
- Recent analyst price-target increases have reinforced bullish sentiment around the precision-medicine platform.
- Trading volume ran above the stock's recent average, reflecting broad-based buying interest.
Opening Summary
SOPHiA GENETICS (SOPH), a Swiss-headquartered, AI-native healthcare technology company behind the SOPHiA DDM™ genomic and multimodal data platform, saw its shares advance 3.84% in the latest session. The stock closed at $8.65, a gain of $0.32 versus the prior close of $8.33, and briefly touched $8.68 intraday — a new 52-week high. The move marked a continuation of a powerful multi-week advance that has pushed the shares up roughly 85% year to date, as investors continue to reward the company's accelerating revenue growth, improving path toward profitability, and deepening biopharma relationships.
Post-Earnings Momentum and Raised Guidance
The foundation for the stock's sustained strength was laid earlier in August, when the company reported second-quarter results that beat top-line expectations. Revenue rose 27% year over year to $23.3 million, ahead of consensus estimates near $21.7 million, while platform analysis volume reached a record 115,000 patient analyses. U.S. revenue climbed 64%, liquid-biopsy revenue jumped 80%, and net dollar retention improved to 117%.
Critically, management raised its full-year 2026 revenue outlook to a range of $94 million to $96 million, up from a prior forecast of $92 million to $94 million, implying 22% to 24% growth. Although the company remains unprofitable on a net basis, its adjusted EBITDA loss narrowed 27% year over year, and executives reaffirmed a target of approaching adjusted-EBITDA breakeven by the end of 2026. That improving operating-leverage story has kept buyers engaged in the weeks following the report.
AstraZeneca Companion-Diagnostics Partnership
A central catalyst behind the recent price rally is the company's first companion-diagnostics (CDx) agreement with AstraZeneca (AZN). Under the multi-year collaboration, SOPHiA GENETICS will develop, validate, and commercialize two companion-diagnostic programs — one for solid tumors and one for hematological (blood) cancers — supporting AstraZeneca's precision-oncology therapies. The deal represents a meaningful validation of the SOPHiA DDM™ platform's regulatory and clinical capabilities and is expected to contribute more substantially to growth from 2027 onward.
Analyst Upgrades and Price-Target Raises
Wall Street's response to the quarterly report and the AstraZeneca announcement has reinforced the bullish tone. H.C. Wainwright raised its price target to $14 from $12 and maintained a Buy rating, while BTIG lifted its target to $9 from $8, also reiterating a Buy. TD Cowen maintained its Buy rating following the results. This clustering of upward revisions has helped sustain positive sentiment, particularly given the stock's relatively small analyst coverage and its status as a high-growth, AI-healthcare story.
Technical Breakout to a 52-Week High
The latest session's advance also carried a distinctly technical character. By pushing through prior resistance and setting a new 52-week high of $8.68, SOPH cleared a level that had acted as a ceiling in recent trading. Breakouts to fresh highs often attract momentum-oriented and trend-following buyers, amplifying intraday gains. The stock's 50-day and 200-day moving averages remain well below the current price, underscoring the strength of the medium- and longer-term uptrend.
Market Context and Trading Activity
Trading activity in the latest session was heavier than typical, with volume running above the stock's recent daily average — a sign that the advance was supported by genuine participation rather than thin, low-liquidity trading. The move occurred against a backdrop of continued investor enthusiasm for artificial-intelligence applications in healthcare and precision medicine, a theme that has lifted valuations across the sector. While the broader market has been mixed, growth-oriented healthcare technology names with improving fundamentals and expanding partnerships have continued to attract capital.
What Comes Next for SOPH
Looking ahead, investors will be watching several developments. The company's next quarterly report is expected around early November, when attention will focus on whether revenue growth remains above 20% and whether the adjusted-EBITDA-loss trajectory stays on track toward breakeven. Progress on the AstraZeneca companion-diagnostic programs and the proposed joint venture with Memorial Sloan Kettering will also be closely monitored, as will continued adoption of liquid-biopsy and enhanced-exome applications. Risks include the company's ongoing net losses, the need to execute on a growing implementation backlog, and potential dilution from its recent capital raise. As with any high-growth, pre-profitability story, valuation and execution risk remain key considerations for traders.
Trending AI Robots
Tickeron's Trending AI Robots page highlights AI-powered trading bots that are currently performing well in live market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under present conditions are featured in this curated section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to explore data-driven approaches to the market. Visit the Trending AI Robots page to see which strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
SOPH's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SOPH turned positive on August 04, 2026. Looking at past instances where SOPH's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on SOPH as a result. In of 120 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SOPH advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 127 cases where SOPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SOPH broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SOPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.857) is normal, around the industry mean (7.638). SOPH has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.808). SOPH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.726). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (6.998) is also within normal values, averaging (6.460).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement